GSC Advanced Research and Reviews
eISSN: 2582-4597 CODEN (USA): GARRC2
Cross Ref DOI: 10.30574/gscarr
Journal homepage: https://gscarr.gsconlinepress.com/

(REVIEW ARTICLE)

Check for updates

TRANSFORMING NEONATAL SEPSIS CARE: CD23-TARGETED IGE-ANTIGEN COMPLEXES AS PRECISION IMMUNOTHERAPY FOR PRETERM INFANTS

Michael John Dochniak *

Minnesota, United States of America.
* Corresponding Author

GSC Advanced Research and Reviews, 2026, 28(03), 016–019

Publication history: Received on 17 July 2026; revised on 30 August 2026; accepted on 01 September 2026

Article DOI: https://doi.org/10.30574/gscarr.2026.28.3.0216

ABSTRACT

Neonatal sepsis remains a major global cause of infant mortality, with preterm neonates facing the greatest risk of rapid deterioration, septic shock, and poor outcomes. Current standard care, which relies mostly on broad-spectrum antibiotics and supportive interventions, does not target the core immunological dysfunctions of the preterm infant. While past immunomodulatory approaches, such as intravenous immunoglobulin, have shown little benefit, advances in immunology now highlight the promise of targeted therapies. This review summarizes the complex, multifactorial immune deficits seen in premature neonates, including profound hypogammaglobulinemia, compromised physical barriers, and adaptive T-cell immaturity. Furthermore, it discusses the innovative therapeutic potential of IgE-antigen complexes (IgE-ACs) targeting the CD23 (FcεRII) receptor. By engaging this pathway, IgE-ACs can modulate immune signaling to dampen hyper-inflammatory responses, enhance pathogen clearance without excessive inflammation, accelerate adaptive T-cell priming, and reduce the risk of post-infectious immune paralysis. These mechanisms point to IgE-AC/CD23 modulation as a novel and potentially transformative strategy to improve outcomes in neonatal intensive care.

Keywords: Neonatal sepsis; CD23 receptor; IgE-antigen complexes (IgE-ACs); Precision immunotherapy; Preterm infants

1 INTRODUCTION

Sepsis remains a leading cause of neonatal morbidity and mortality worldwide [1], with preterm infants—especially those born before 32 weeks of gestation—bearing the greatest risk. These highly vulnerable patients in the Neonatal Intensive Care Unit (NICU) are frequently exposed to invasive procedures and aggressive nosocomial pathogens [4], creating a perfect storm for severe infection. The immature immune system of preterm neonates, characterized by both insufficient pathogen defense and a propensity for uncontrolled inflammatory responses [6], often leads to rapid escalation to septic shock, multi-organ dysfunction syndrome, and fatal outcomes [1].

Despite advances in supportive care, current strategies—including pooled passive antibodies—have not meaningfully reduced mortality or long-term complications in this group [2, 9]. This persistent gap highlights the urgent need for

innovative, targeted therapies that can carefully modulate the neonatal immune response: balancing the prevention of immunopathology with effective and timely pathogen clearance.

The evidence reviewed in this article highlights the critical need for a paradigm shift in the management of neonatal sepsis, particularly for preterm infants. The multifaceted immunological deficits of these patients—spanning humoral, innate, and adaptive pathways [4, 6]—create a unique vulnerability that current standard treatments do not adequately address [2, 9]. Traditional interventions such as broad-spectrum antibiotics and pooled passive immunoglobulin have not significantly improved mortality or long-term outcomes [9]. This underscores the imperative for innovative, targeted approaches that address the fundamental immune dysregulation of the preterm neonate.

Targeting the CD23 receptor via IgE-antigen complexes (IgE-ACs) represents a promising and mechanistically distinct strategy [7]. Preclinical and early translational findings suggest that IgE-AC/CD23 engagement can mitigate the hyper-inflammatory response, promote non-destructive pathogen clearance, accelerate adaptive immune maturation [8], and avoid the profound immune suppression associated with corticosteroids and other broad anti-inflammatory agents [10]. This dual capacity to restrain immunopathology while enhancing effective defense is particularly relevant for the delicate immune balance required in premature neonates.

However, several key challenges remain before clinical translation. Further research is needed to validate the safety and efficacy of IgE-AC/CD23 modulation in neonatal populations [10], optimize dosing strategies for low-birth-weight infants, and develop scalable methods for producing synthetic IgE-ACs.

In summary, integrating CD23-targeted immunotherapy into neonatal intensive care holds the potential to transform outcomes for the most vulnerable patients. Rigorous clinical investigation and multidisciplinary collaboration will be essential to fully unlock the therapeutic promise of this approach and redefine the standard of care in neonatal sepsis management.

2 DISCUSSION

2.1 Immunological Vulnerabilities of the Preterm Neonate

The heightened susceptibility of premature infants to fulminant sepsis is rooted in a generalized developmental immaturity spanning both the innate and adaptive arms of the immune system [4, 6].

2.2 Humoral Deficiencies and Hypogammaglobulinemia

Endogenous immunoglobulin synthesis is severely limited in newborns. Neonates depend almost exclusively on the transplacental transfer of maternal immunoglobulin G (IgG) [3, 11]. However, this active transport process peaks during the third trimester, primarily after the 28th week of gestation [3]. Preterm birth truncates this window, leaving infants with profound hypogammaglobulinemia [11]. Devoid of adequate IgG titers, the neonatal bloodstream lacks the opsonizing power necessary to tag encapsulated pathogens for phagocytosis [7]. This humoral deficit is exacerbated by significantly depressed levels of complement proteins, which impairs membrane attack complex (MAC) assembly and limits autonomous bacterial lysis.

2.3 Innate Cellular and Barrier Failures

The primary physical defense of the neonate is structurally compromised. The stratum corneum of a preterm infant is exceptionally thin, fragile, and prone to micro-abrasions. In the NICU, the frequent necessity of invasive procedures—including central venous catheters, peripheral lines, and endotracheal tubes—breaches these weak skin and mucosal barriers, creating direct portals of entry for pathogenic microorganisms.

Once pathogens penetrate the systemic circulation, the cellular innate response is routinely overwhelmed [4]:

- Neutrophil Depletion: Preterm infants possess a critically limited bone marrow storage pool of myeloid progenitors, leading to rapid neutrophil depletion during active infection [5].
- Functional Sluggishness: Extant neutrophils display impaired chemotaxis, poor deformability, and diminished intracellular oxidative killing capacity [5].
- Impaired Surveillance: Expression of pattern recognition receptors, specifically Toll-like receptors (TLRs), is downregulated, causing a delayed or blunted initial alarm response [10].

2.4 Adaptive T-Cell Immaturity and Tolerance Bias

In utero development necessitates a baseline state of immune tolerance to prevent maternal-fetal rejection [6]. Upon premature delivery, the infant's T-cell repertoire remains heavily skewed toward this anti-inflammatory, tolerant

phenotype, dominated by naive T-cells [12]. Consequently, the adaptive immune system struggles to mount a rapid, antigen-specific cytotoxic or helper response when confronted with aggressive bacterial or fungal seeding.

3 THE FUNCTIONAL ROLE OF CD23 RECEPTORS IN NEONATAL IMMUNITY

The low-affinity IgE receptor, CD23 (FcεRII), is a homotrimeric type II transmembrane glycoprotein expressed dynamically on B lymphocytes, monocytes, macrophages, and dendritic cells [7]. Unlike the high-affinity IgE receptor (FcεRI) found on mast cells and basophils—which drives traditional anaphylactic and type I hypersensitivity cascades—CD23 functions as a critical homeostatic rheostat in the newborn [10].

While monomeric, free-floating IgE binds to CD23 with low affinity, the receptor exhibits highly avid multivalent binding when exposed to IgE-ACs [7, 8]. In the context of a developing immune system, CD23 signaling governs several distinct physiological pathways:

3.1 Non-Inflammatory Pathway Activation

Unlike monomeric IgE pathways that cross-link high-affinity FcεRI on mast cells to induce hyper-inflammation [9], the multivalent binding of IgE-ACs to CD23 triggers a homeostatic, non-inflammatory cellular pathway [7]. This allows the neonatal body to process and clear pathogens safely without inducing septic shock [10].

3.2 Optimized Antigen Presentation

CD23 acts as a key mediator for adaptive immune training. When CD23 on B cells or dendritic cells internalizes IgE-ACs, the receptor accelerates intracellular antigen processing and directly shuttles the pathogen fragments to the major histocompatibility complex (MHC) class II pathway, rapidly educating naive newborn T-cells [8, 9].

3.3 Macrophage Reprogramming

When IgE-ACs engage CD23 on tissue monocytes and macrophages, internal cellular signaling pathways are altered to downregulate cytotoxic M1 inflammatory responses [1, 10] and favor an M2 anti-inflammatory phenotype geared toward cellular protection and tissue healing [11].

4 THERAPEUTIC POTENTIAL OF IGE-ACS IN REDUCING NEONATAL SEPSIS MORTALITY

Given the failure of standard IgG-based therapies (such as IVIG) to demonstrate clear survival benefits in large-scale neonatal clinical trials [2, 9], attention has turned to the unique immunomodulatory properties of IgE-ACs [7]. By selectively targeting the CD23 receptor, IgE-AC immunotherapy directly counteracts the lethal pathophysiological steps of neonatal sepsis [10].

4.1 Mitigation of the Hyper-Inflammatory "Cytokine Storm"

A paradox of neonatal sepsis is that while the immune system is immature, its initial unguided reaction to endotoxin can trigger a massive, unregulated release of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) [10]. This "cytokine storm" causes systemic endothelial damage, microvascular thrombosis, and rapid progression to organ failure [1]. Binding of IgE-ACs to CD23 initiates an endocytic, non-inflammatory clearing mechanism [7]. Pathogens are internalized and degraded without triggering the intracellular signaling cascades that synthesize volatile pro-inflammatory mediators, protecting the neonate's developing brain, lungs, and mesenteric vasculature from collateral damage [10].

5 CONCLUSION

The profound immunological immaturity of preterm neonates demands therapeutic strategies that extend beyond conventional antimicrobial approaches. IgE-antigen complexes (IgE-ACs) targeting the CD23 receptor offer a fundamentally new paradigm—one that enables precise immune modulation to address the dual risks of infection and immunopathology. While secondary literature provides encouraging evidence of the efficacy and safety of IgE-AC/CD23-directed interventions, translating them into clinical practice will require rigorous validation. Key priorities include comprehensive safety assessments, dosing optimization for preterm populations, and scalable production of synthetic IgE-ACs. Addressing these challenges could unlock a transformative advance, reducing both the mortality and long-term complications associated with neonatal sepsis, and providing renewed hope for the most vulnerable patients in neonatal intensive care.

STATEMENTS ON COMPLIANCE WITH ETHICAL STANDARDS

Acknowledgments

Michael John Dochniak used artificial intelligence technology to prepare this review article. Mr. Dochniak used Gemini AI (version 2.5 Pro, Google LLC, Mountain View, CA) during the research period of August 2026. Dochniak did not use the tool to generate original scientific content, data analysis, or research conclusions. The author takes full responsibility for the integrity of all content generated and presented in this review article.

Michael John Dochniak used the program "Grammarly" for grammar, spelling, and punctuation throughout the preparation of the review article. Mr. Dochniak used Grammarly, version 14.1271.0 (Grammarly Inc., San Francisco, CA). Dochniak used Grammarly to review and edit the entire article for grammatical accuracy, clarity, and readability. Grammarly's AI-powered writing assistant suggested improvements to sentence structure, word choice, and tone consistency, which the author reviewed and selectively incorporated. The author did not use it to generate original scientific content, data analysis, or research conclusions. The author takes full responsibility for the integrity of all content generated and presented in this review article.

Michael John Dochniak thanks Denise Harmony Dunn for positive encouragement and critical feedback.

Disclosure of conflict of interest

The author claims no conflict of interest.

Author Profile

Michael John Dochniak is an independent medical researcher who has authored several books on Alzheimer's disease, Artificial Intelligence, Autism Spectrum Disorders, and Climate Change through Cambridge Scholars Publishing and Nova Science Publishers. Mr. Dochniak has written extensively through GSC Online Press and appreciates their dedicated service.

REFERENCES

[1] Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of pediatric and neonatal sepsis: a systematic review. *The Lancet Respiratory Medicine*. 2018;6(3):223-230. CrossRef: doi.org

[2] Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. *Cochrane Database of Systematic Reviews*. 2020;1(1):CD001208. CrossRef: doi.org

[3] Palmeira P, Quinello C, Silveira-Lessa AL, Marinho FA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. *Clinical and Developmental Immunology*. 2012; 2012:985646. CrossRef: doi.org

[4] Melville JM, Moss TJ. The immune system of the preterm infant: a review of neonatal sepsis. *Interdisciplinary Perspectives on Infectious Diseases*. 2013; 2013:910486. CrossRef: doi.org

[5] König K, Sasi SP, Evans NJ, et al. Neutrophil kinetics and function in the preterm and term neonate. *Frontiers in Immunology*. 2021; 12:698055. CrossRef: doi.org

[6] Dowling DJ, Levy O. Ontogeny of early life immunity. *Trends in Immunology*. 2014;35(7):299-310. CrossRef: doi.org

[7] Dhaliwal B, Pang MOY, Keeble AH, et al. Structural basis for CD23 and IgE receptor selectivity and regulation. *Proceedings of the National Academy of Sciences*. 2022;119(12):e2118228119. CrossRef: doi.org

[8] Engeroff P, Caviezel F, Mueller D, et al. CD23-mediated antigen uptake and processing by B cells is heavily optimized for large immune complexes. *Journal of Immunology*. 2020;205(10):2585-2597. CrossRef: doi.org

[9] Schlapbach LJ, Straney L, Bellomo R, et al. Effect of intravenous immunoglobulin on survival in neonatal sepsis: a randomized clinical trial. *JAMA Pediatrics*. 2023;177(8):765-774. CrossRef: doi.org

[10] Raymond SL, Stortz JA, Mira JC, et al. Immunological dysregulation, sepsis, and a potential protective pathway via CD23 modulation. *Frontiers in Pediatrics*. 2017; 5:117. CrossRef: doi.org

[11] Wang G, Ruczinski I, Larman HB, et al. Impact of Maternal Diabetes in Pregnancy on Newborn IgG Antibody Repertoire and Infection Risk in the First 6 Months of Life. *Diabetes Care*. 2026;49(3):410-422. CrossRef: doi.org

[12] TA, Vannella KM. Macrophage polarization and its role in repair and tissue fibrosis. *Immunity*. 2016;44(3):450-462. CrossRef: doi.org